EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada

Winson Y Cheung, Setareh Samimi, Kim Ma, Gregory John Knight, Shaqil Kassam, Bruce Colwell, Annie Beaudoin, Mark David Vincent, Mateya Trinkaus, Alain Filion, Katerine Marquis, Hatim Karachiwala und 12 weitere

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2023.10.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Winson Y Cheung und 23 weiteren Autor:innen. Beteiligte Einrichtung: Tom Baker Cancer Centre, Calgary, AB, Canada. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer (mCRC). This study aimed to address gaps in real-world evidence (RWE) including patient characteristics, treatment safety (primary objective), and effectiveness (secondary objective) for first-line ABP 215 therapy in Canadian patients with mCRC. MATERIALS AND METHODS: Retrospective data were collected in 2 waves, at least 1 year (Wave 1) or 2 years (Wave 2) after commercial availability of ABP 215 at each participating site. RESULTS: A total of 75 patients from Wave 1 and 164 patients from Wave 2 treated with a minimum of 1 cycle of ABP 215 were included. At least one safety event of interest (EOI) was recorded for 34.7% of Wave 1 and 42.7% of Wave 2 patients. The median progression free survival (PFS) for Wave 1 and 2 patients were 9.47 (95% confidence interval [CI]: 6.71, 11.90) and 21.38 (95% CI: 15.82, not estimable) months, respectively. Median overall survival was not estimable for Wave 1 and was 26.45 months for Wave 2. CONCLUSION: The safety and effectiveness of ABP 215 observed in this real-world study were comparable to clinical trial findings and to other RWE with longer PFS in the current study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsColonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsHumansBevacizumabCanadaRetrospective Studies

Stichwörter der Autor:innen

Anti-angiogenesisEvents of interestFirst-lineReal-world evidenceRetrospective data

Substanzen

BevacizumabBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Tom Baker Cancer Centre, Calgary, AB, Canada.
  • CIUSSS-du Nord-de-l'Île-de-Montréal, Montréal, QC, Canada.
  • CISSS de Laval, Laval, QC, Canada.
  • Grand River Regional Cancer Centre, Kitchener, ON, Canada.
  • Southlake Regional Health Centre, Newmarket, ON, Canada.
  • Nova Scotia Health Authority Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

Förderung

  • Amgen

Zitieren

APA

Cheung, W. Y., Samimi, S., Ma, K., Knight, G. J., Kassam, S., Colwell, B., Beaudoin, A., Vincent, M. D., Trinkaus, M., Filion, A., Marquis, K., Karachiwala, H., Asmis, T., Sideris, L., Wani, R. J., Ngan, E., Inam, N., Du, Y., Nunez, L., …, & Cirone Morris, C. (2024). Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.10.007

Vancouver

Cheung WY, Samimi S, Ma K, Knight GJ, Kassam S, Colwell B, et al. Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2023.10.007

BibTeX
@article{Cheung2024,
  author = {Cheung, Winson Y and Samimi, Setareh and Ma, Kim and Knight, Gregory John and Kassam, Shaqil and Colwell, Bruce and Beaudoin, Annie and Vincent, Mark David and Trinkaus, Mateya and Filion, Alain and Marquis, Katerine and Karachiwala, Hatim and Asmis, Timothy and Sideris, Lucas and Wani, Rajvi J and Ngan, Elaine and Inam, Naila and Du, Yinhao and Nunez, Leyla and Eberg, Maria and Alemayehu, Mistre and Meyer, Pierre-Francois and Mancini, Johanna and Cirone Morris, Carlye},
  title = {Real-World Safety and Effectiveness of a Bevacizumab Biosimilar (ABP 215) in Metastatic Colorectal Cancer Patients in Canada},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2023.10.007}
}
Kostenlos starten →